Rokit Healthcare, a company specializing in AI-driven bioprinting and organ regeneration medicine, announced on June 10 that it presented its kidney regeneration platform at the 61st European Renal Association (ERA 2025), the world’s most prestigious nephrology conference, held in Austria from June 4 to June 7. The company stated that its technological capabilities were recognized in the global medical market during the event.
The technology presented is an omentum-based therapeutic platform that promotes fundamental tissue regeneration by inducing angiogenesis in damaged kidney tissue and suppressing fibrosis. The company explained that, by suppressing inflammatory responses while simultaneously improving blood flow, this mechanism offers a new therapeutic paradigm in areas such as chronic kidney disease and acute kidney injury, which have been difficult to address with existing treatments.
A company representative stated, “The ERA presentation was a meaningful opportunity to share the scientific validity and clinical applicability of our technology with the global academic community,” adding, “It is being highlighted as a breakthrough that can delay the initiation of dialysis for kidney failure patients who previously had no alternatives other than organ transplantation or dialysis.”
The project is currently being conducted as a research initiative with Asan Medical Center in Seoul, Boramae Medical Center at Seoul National University College of Medicine, and the National Consortium for Regenerative Medical Technology Development. The company is preparing to enter pilot clinical trials within the year. In addition, it is developing a personalized treatment strategy that integrates AI-based prognosis and prediction technology for end-stage renal disease (ESRD).
Rokit Healthcare has already secured a technological edge over competitors based on domestic patents. Building on this foundation, the company is preparing to develop AI-based disease prediction models for a wider range of organs in the future.
Rokit Healthcare CEO Yoo Seokhwan said, “A structural approach to regenerating kidney function has long been one of the most difficult challenges, but our technology offers a viable alternative,” adding, “As a treatment that can delay the need for dialysis, it will be a game-changer that significantly improves patients’ quality of life.”
He further stated, “Based on the achievements of national research projects and global academic presentations, we will accelerate the commercialization of our technology and, starting with the pilot clinical trial at Asan Medical Center in the second half of the year, we plan to make a full-scale entry into the market.”
Last year, at the Asia Pacific Congress of Nephrology (APCN), the company also received the Outstanding Poster Award for its “decellularization-recellularization-based kidney regeneration technology,” internationally demonstrating the research achievements and completeness of its technology.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
